{
    "root": "3622f4f5-48bd-9035-e063-6294a90afac2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tacrolimus",
    "value": "20250602",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TACROLIMUS",
            "code": "WM0HAQ4WNM",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00864"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": null,
    "contraindications": {
        "text": "intravenous ( iv ) recommended patients tolerate oral formulations ( capsules ) . ( 2.1 , 2.2 ) administer capsules consistently without food . ( 2.1 ) therapeutic monitoring recommended . ( 2.1 , 2.6 ) avoid eating grapefruit drinking grapefruit juice . ( 2.1 ) adjustments african-american patients ( 2.2 ) , hepatic renal impaired . ( 2.4 , 2.5 ) complete dosing information , full prescribing information . adult patient population initial oral ( formulation ) whole blood trough concentration range kidney transplant azathioprine 0.2 mg/kg/day capsules , divided two doses , every 12 hours month 1 3 : 7 20 ng/ml month 4 12 : 5 15 ng/ml mmf/il-2 receptor antagonist 0.1 mg/kg/day capsules , divided two doses , every 12 hours month 1 12 : 4 11 ng/ml liver transplant corticosteroids 0.1 0.15 mg/kg/day capsules , divided two doses , every 12 hours month 1 12 : 5 20 ng/ml heart transplant azathioprine mmf 0.075 mg/kg/day capsules , divided two doses , every 12 hours month 1 3 : 10 20 ng/ml month \u2265 4 : 5 15 ng/ml pediatric patient population initial oral ( formulation ) whole blood trough concentration range liver transplant 0.15 0.2 mg/kg/day capsules divided two doses , every 12 hours month 1 12 : 5 20 ng/ml mmf= mycophenolate mofetil",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "tacrolimus capsules contraindicated patients hypersensitivity tacrolimus . tacrolimus injection contraindicated patients hypersensitivity hco-60 ( polyoxyl 60 hydrogenated castor oil ) . hypersensitivity symptoms reported include dyspnea , rash , pruritus , acute respiratory distress syndrome [ ( 6 ) ] .",
    "contraindications_original": "Intravenous (IV) use recommended for patients who cannot tolerate oral formulations (capsules). ( 2.1 , 2.2 ) Administer capsules consistently with or without food. ( 2.1 ) Therapeutic drug monitoring is recommended. ( 2.1 , 2.6 ) Avoid eating grapefruit or drinking grapefruit juice. ( 2.1 ) See dosage adjustments for African-American patients ( 2.2 ), hepatic and renal impaired. ( 2.4 , 2.5 ) For complete dosing information, see the full prescribing information. ADULT Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Kidney Transplant With azathioprine 0.2 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 3: 7 to 20 ng/mL Month 4 to 12: 5 to 15 ng/mL With MMF/IL-2 receptor antagonist 0.1 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 12: 4 to 11 ng/mL Liver Transplant With corticosteroids only 0.1 to 0.15 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 12: 5 to 20 ng/mL Heart Transplant With azathioprine or MMF 0.075 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 3: 10 to 20 ng/mL Month \u2265 4: 5 to 15 ng/mL PEDIATRIC Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Liver Transplant 0.15 to 0.2 mg/kg/day capsules divided in two doses, every 12 hours Month 1 to 12: 5 to 20 ng/mL MMF= Mycophenolate mofetil",
    "adverseReactions_original": "Tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. Tacrolimus injection is contraindicated in patients with a hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil). Hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome\n \n  [see\n  \n   Adverse Reactions (6)]\n \n  .",
    "drug": [
        {
            "name": "Tacrolimus",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00864"
        }
    ]
}